LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Viknaswaran, N L"
  2. AU="Luo, Huixin"
  3. AU="Li, Gordon"
  4. AU=Bauchner Howard
  5. AU=Markiewski Maciej M

Suchergebnis

Treffer 1 - 1 von insgesamt 1

Suchoptionen

Artikel ; Online: Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.

Tsan, S E H / Viknaswaran, N L / Cheong, C C / Cheah, S / Ng, K T / Mong, S X Y / Wang, C Y

Anaesthesia

2023  Band 78, Heft 9, Seite(n) 1153–1161

Abstract: Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects. We aimed to investigate the effect of prophylactic intravenous tranexamic acid on thromboembolic outcomes in patients ...

Abstract Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects. We aimed to investigate the effect of prophylactic intravenous tranexamic acid on thromboembolic outcomes in patients undergoing non-cardiac surgery. The MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials were searched. Randomised controlled trials comparing intravenous tranexamic acid with placebo or no treatment in patients undergoing non-cardiac surgery were included. The primary outcome was a composite of peri-operative cardiovascular thromboembolic events, defined as any deep vein thrombosis, pulmonary embolism, myocardial ischaemia/infarction or cerebral ischaemia/infarction. A total of 191 randomised controlled trials (40,621 patients) were included in the review. The primary outcome occurred in 4.5% of patients receiving intravenous tranexamic acid compared with 4.9% of patients in the control group. Our analysis showed that there was no difference between groups for composite cardiovascular thromboembolic events (risk ratio 1.02, 95%CI 0.94-1.11, p = 0.65, I
Mesh-Begriff(e) Humans ; Tranexamic Acid/adverse effects ; Antifibrinolytic Agents/adverse effects ; Thromboembolism/prevention & control ; Blood Transfusion ; Myocardial Infarction ; Blood Loss, Surgical/prevention & control
Chemische Substanzen Tranexamic Acid (6T84R30KC1) ; Antifibrinolytic Agents
Sprache Englisch
Erscheinungsdatum 2023-06-14
Erscheinungsland England
Dokumenttyp Systematic Review ; Meta-Analysis ; Journal Article ; Review
ZDB-ID 80033-8
ISSN 1365-2044 ; 0003-2409
ISSN (online) 1365-2044
ISSN 0003-2409
DOI 10.1111/anae.16058
Signatur
Zs.A 388: Hefte anzeigen Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Kategorien

Zum Seitenanfang